Fagron NV Posts 9.2% Revenue Growth, 10.9% REBITDA Increase in FY 2025
Event summary
- Fagron NV reported €952.2 million in revenue for FY 2025, up 9.2% YoY (12.9% at CER).
- REBITDA increased 10.9% YoY to €192.9 million, with a margin of 20.3%.
- Operating cash flow reached €155.3 million, free cash flow up 29.0% YoY to €125.9 million.
- Completed 12 acquisitions across all regions and segments in 2025.
- Proposed dividend of €0.40 per share, up 14.3% YoY.
The big picture
Fagron NV's strong FY 2025 performance reflects its diversified business model and disciplined commercial execution. The company's ability to drive growth across all regions, coupled with its M&A strategy, positions it well in the competitive pharmaceutical compounding sector. The focus on operational excellence and cash generation underscores its strategic resilience amid broader industry challenges.
What we're watching
- Execution Risk
- Whether Fagron can sustain its M&A integration momentum and capture synergies.
- Market Dynamics
- How regional demand trends, particularly in Latin America and North America, will impact growth.
- Financial Strategy
- The pace at which Fagron reduces its leverage ratio while funding expansion projects.
Related topics